Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW28012 in Combination Regimens for Advanced Solid Tumors (Ib/II, China)
CTR20255163Phase 2Active
- Sponsor
- Sinovent
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of xnw28012 in pancreatic adenocarcinoma (PDAC), epithelial ovarian cancer (EOC), cervical cancer (mCC), metastatic colon cancer (mCRC), head and neck squamous cell carcinoma (HNSCC), sponsored by Sinovent. Started Mar 2026; status: active.
02
Drugs
xnw28012
03
Conditions
pancreatic adenocarcinoma (PDAC)epithelial ovarian cancer (EOC)cervical cancer (mCC)metastatic colon cancer (mCRC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20255163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255163.